ABL Bio Presents Posters at AACR... Unveils Distinctive Preclinical Data

Powerful Anticancer Effects Demonstrated in Preclinical Studies
Excellent Safety Profile Confirmed

ABL Bio, a company specializing in bispecific antibodies, announced on the 23rd that poster presentations for ABL206 (NEOK001) and ABL209 (NEOK002), held at the American Association for Cancer Research (AACR) Annual Meeting on the 20th (local time), were successfully concluded.

ABL206 and ABL209 are bispecific antibody ADC pipelines developed by ABL Bio. Both ABL206 and ABL209 are currently undergoing Phase 1 clinical trials in the United States, and the global development and commercialization of these two pipelines are being handled by NEOK Bio, a company established by ABL Bio. NEOK Bio plans to accelerate clinical development for both pipelines and announce initial clinical data in 2027.

Bispecific antibody ADCs are a technology that increases safety and efficacy by simultaneously targeting two antigens expressed on cancer cells, thereby delivering potent cytotoxic agents (payloads) more precisely to the cancer cells. ABL206 targets both B7-H3 and ROR1, while ABL209 targets both EGFR and MUC1.

According to the posters released at AACR, ABL206 demonstrated rapid internalization into cancer cells by binding to B7-H3 and ROR1 in preclinical experiments and showed strong anticancer effects. In addition, the bystander effect, which impacts neighboring cancer cells lacking the target antigens, was also confirmed. Furthermore, ABL206 induced tumor regression in various patient-derived xenograft (PDX) models and demonstrated tumor elimination effects even in cancers that recurred after conventional treatments.

ABL209 was designed to reduce binding to normal tissues while exhibiting high binding affinity in cancer cells expressing both target antigens. It also demonstrated strong anticancer effects in PDX models, and based on its excellent pharmacokinetics (PK) and safety profile, showed the potential to improve the therapeutic window.

Sanghoon Lee, CEO of ABL Bio, stated, "Bispecific antibody ADCs are attracting attention as next-generation technology that can overcome the limitations of conventional monoclonal antibody ADCs. These preclinical research results clearly demonstrate the high potential of bispecific antibody ADCs. Within ABL Bio, we are actively conducting research on ADCs following ABL206 and ABL209, including dual payload ADCs. The next generation of ADC development at ABL Bio has now officially begun. We ask for your continued interest and support."

ABL Bio is developing a diverse pipeline at both preclinical and clinical stages based on its bispecific antibody platform, 'Grabody.' Clinical projects for ten pipelines—including ABL301 (SAR446159), ABL001 (Tovecimig), ABL111 (Givastomig), ABL503 (Ragistomig), ABL105 (Nesfrotamig), ABL104 (YH32364), ABL103, ABL202 (CS5001/LCB71), ABL206 (NEOK001), and ABL209 (NEOK002)—are being conducted in various countries including the United States, China, Australia, and Korea. Follow-up clinical trials for ABL301 (SAR446159), which completed Phase 1 in the United States, will be carried out by Sanofi. ABL001 (Tovecimig), currently in Phase 2/3 trials for patients with cholangiocarcinoma, has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). ABL111 (Givastomig), being co-developed with NovaBridge, has initiated Phase 2 clinical trials for combination therapy with Nivolumab and chemotherapy, and additional data on Phase 1b will be presented at a global conference in the second half of this year. In addition, several preclinical pipelines—including bispecific antibody ADCs and dual payload ADCs—are continuously under research and development.

This content was produced with the assistance of AI translation services.